Gilead Q1: ex-Veklury product sales +15% to $5.7B; lowers GAAP EPS guidance to $4.75-$5.15

GILEAD SCIENCES, INC.

2023-Q1 EPS reported $0.80 revenue$6,352,000,000

Q1 total revenue $6.4B (-4% YoY); product sales ex-Veklury up 15% to $5.7B.
HIV sales $4.2B (+13%); Biktarvy sales $2.7B (+24%); Oncology sales $670M (+59%).
Non-GAAP diluted EPS $1.37 vs $2.12 YoY; GAAP EPS $0.80 vs $0.02.
GAAP EPS guidance lowered to $4.75-$5.15 from $5.30-$5.70; non-GAAP unchanged $6.60-$7.00.
Cash & equivalents $7.2B; paid $969M dividends, repurchased $400M stock in Q1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

GILEAD SCIENCES, INC. reported first quarter of 2023 results: EPS Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022.

Period: first quarter of 2023
EPS: Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022
Result: reported results

Exact text from the filing

Total first quarter 2023 revenue decreased 4% to $6.4 billion compared to the same period in 2022, due to lower Veklury® (remdesivir) sales, partially offset by increased sales in HIV and Oncology.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

GILEAD SCIENCES, INC. reported first quarter of 2023 results: EPS Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022.

Period: first quarter of 2023
EPS: Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022
Result: reported results

Exact text from the filing

Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022

View on SEC.gov

Browse all earnings releases →

GILEAD SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000882095-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.